Antares Pharma, Inc. (ATRS)

[H2R]

SA new article: The word continues to get out:

https://seekingalpha.com/article/4111040-antares-numerous-upcoming-catalysts

A Bright Horizon

It's been a long road for Antares (ATRS) investors to say the least. The company has never turned a profit, and until recently, has never even had a substantial product revenue stream. However, things are beginning to change. Over the next six months, investors can expect the company to hit two major milestones on the road to profitability, and 2018 may be the first year of profitability.

After successful trials, Antares expects an FDA decision on XYosted, an Antares treatment for testosterone deficiency. Antares anticipates an approval by October 20th, and has begun investing in marketing and distribution. Soon thereafter, Antares should start receiving revenue from a Teva (TEVA) AB-rated generic EpiPen, a long-awaited triumph after a series of hiccups pushing back the anticipated launch date into 2018.